Gain Therapeutics Inc (GANX)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$1.33

+0.01 (+0.76%)

Market Cap: $57.61M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

55%(12/22)

Avg Surprise

-13.30%

Streak

4 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.13

Range$-0.13 - $-0.12

3 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$-0.16+19.6%

60d ago$-0.16+19.6%

30d ago$-0.16+19.6%

7d ago$-0.130.0%

Current$-0.13

Revenue Consensus

Range$0 - $0

5 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.08

Range$-0.11 - $-0.07

3 analysts

Revenue Consensus

Range$0 - $0

5 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.08	$-0.11 - $-0.07	-	-	3	-	-
Sep 30, 2026Sep 26EST	-	$-0.13	$-0.13 - $-0.12	-	-	3	1 0 30d	-
Jun 30, 2026Jun 26 Reported Aug 11, 2026Reported Aug 11	$-0.11	$-0.14	$-0.18 - $-0.13	+21.43%	Beat	4	No revisions (30d)	+42.1%
Mar 31, 2026Mar 26 Reported May 11, 2026Reported May 11	$-0.13	$-0.14	$-0.15 - $-0.13	+7.14%	Beat	3	2 0 30d	+18.8%
Dec 31, 2025Dec 25 Reported Mar 26, 2026Reported Mar 26	$-0.11	$-0.14	$-0.15 - $-0.12	+23.77%	Beat	4	1 0 30d	-37.5%
Sep 30, 2025Sep 25 Reported Nov 12, 2025Reported Nov 12	$-0.15	$-0.15	$-0.16 - $-0.14	+0.00%	Beat	3	2 1 30d	+11.8%
Jun 30, 2025Jun 25 Reported Aug 12, 2025Reported Aug 12	$-0.19	$-0.17	$-0.18 - $-0.16	-11.76%	Miss	5	2 1 30d	+54.8%
Mar 31, 2025Mar 25 Reported May 14, 2025Reported May 14	$-0.16	$-0.17	$-0.22 - $-0.14	+5.88%	Beat	4	1 0 30d	+27.3%
Dec 31, 2024Dec 24 Reported Mar 27, 2025Reported Mar 27	$-0.08	N/A	-	+57.33%	Beat	4	2 0 30d	+77.8%
Sep 30, 2024Sep 24 Reported Nov 14, 2024Reported Nov 14	$-0.17	$-0.21	$-0.23 - $-0.18	+19.05%	Beat	3	1 0 30d	+54.1%
Jun 30, 2024Jun 24 Reported Aug 8, 2024Reported Aug 8	$-0.42	$-0.22	$-0.23 - $-0.16	-90.91%	Miss	3	No revisions (30d)	+32.3%
Mar 31, 2024Mar 24 Reported May 14, 2024Reported May 14	$-0.22	$-0.33	$-0.39 - $-0.19	+33.33%	Beat	4	No revisions (30d)	+48.8%
Dec 31, 2023Dec 23 Reported Mar 26, 2024Reported Mar 26	$-0.36	$-0.32	$-0.40 - $-0.26	-12.50%	Miss	4	No revisions (30d)	+7.7%
Sep 30, 2023Sep 23 Reported Nov 14, 2023Reported Nov 14	$-0.37	$-0.46	$-0.51 - $-0.38	+19.57%	Beat	5	No revisions (30d)	+2.6%
Jun 30, 2023Jun 23 Reported Aug 10, 2023Reported Aug 10	$-0.62	$-0.38	$-0.41 - $-0.10	-63.16%	Miss	4	No revisions (30d)	-44.2%
Mar 31, 2023Mar 23 Reported May 12, 2023Reported May 12	$-0.43	$-0.39	$-0.41 - $-0.37	-10.26%	Miss	3	No revisions (30d)	-53.6%
Dec 31, 2022Dec 22 Reported Mar 23, 2023Reported Mar 23	$-0.39	$-0.36	$-0.42 - $-0.33	-8.33%	Miss	4	No revisions (30d)	-50.0%
Sep 30, 2022Sep 22 Reported Nov 10, 2022Reported Nov 10	$-0.38	$-0.46	$-0.54 - $-0.39	+17.39%	Beat	4	No revisions (30d)	+2.6%
Jun 30, 2022Jun 22 Reported Aug 8, 2022Reported Aug 8	$-0.43	$-0.31	$-0.33 - $-0.29	-38.71%	Miss	3	1 0 30d	-43.3%
Mar 31, 2022Mar 22 Reported May 16, 2022Reported May 16	$-0.28	$-0.37	$-0.43 - $-0.28	+24.32%	Beat	4	1 0 30d	+44.0%
Dec 31, 2021Dec 21 Reported Mar 24, 2022Reported Mar 24	$-0.26	$-0.49	$-0.51 - $-0.47	+46.94%	Beat	3	No revisions (30d)	-
Sep 30, 2021Sep 21 Reported Nov 12, 2021Reported Nov 12	$-0.39	$-0.33	$-0.40 - $-0.28	-18.18%	Miss	2	2 0 30d	+5.0%
Jun 30, 2021Jun 21 Reported Aug 11, 2021Reported Aug 11	$-0.30	$-0.23	$-0.24 - $-0.23	-30.43%	Miss	2	No revisions (30d)	+4.9%
Mar 31, 2021Mar 21 Reported May 10, 2021Reported May 10	$-0.50	$-0.13	$-0.18 - $-0.09	-284.62%	Miss	2	No revisions (30d)	-
Dec 31, 2020Dec 20 Reported Mar 22, 2021Reported Mar 22	$0.00	$0.00	-	N/A	Beat	-	-	-
Sep 30, 2020Sep 20 Reported Dec 31, 2020Reported Dec 31	$-0.41	$0.00	-	N/A	Miss	-	-	-
Sep 30, 2019Sep 19 Reported Dec 31, 2019Reported Dec 31	$-0.32	$0.00	-	N/A	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-2.66	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-268.30%	ROIC	-167.72%
Financial Health
Debt/Equity	0.03x	Interest Coverage	N/A
Current Ratio	4.36x	Quick Ratio	4.36x
Trading Statistics
Beta	0.19	Avg Volume	506.31K
52-Week High	$4.34	52-Week Low	$1.29

Technical Indicators Dashboard

Moving Averages

SMA 10$1.56

SMA 20$1.68

SMA 50$1.80

SMA 200$1.94

EMA 10$1.52

EMA 20$1.62

EMA 50$1.73

EMA 200$1.90

MACD

Line: -0.10Signal: -0.06Hist: -0.04

ADX

ADX: 19.6+DI: 11.1-DI: 34.9

Aroon & PSAR

Aroon Up36.0

Aroon Down96.0

PSAR$1.75

Bollinger Bands

Upper Band$2.01

Lower Band$1.35

%B Position3955%(Upper)

Band Width-0.02

RSI (14-Day)

Oversold

24.5

Momentum Oscillators

Stoch %K4.2

Stoch %D3.8

Williams %R-93.6

ROC (10d)-22.7%

Momentum-0.39

CCI (20d)-197.8

MFI (14d)25.1

Volatility Measures

ATR (14d)$0.10(7.4%)

StdDev (20d)0.17

Hist Vol60.7%(High)

Volume Flow

VWAP$1.35

OBV10.4M

AD Line-11.4M

CMF (20d)-0.306

Volume Metrics

Avg Vol (20d)526.6K

Vol Ratio1.0x

VWMA (20d)$1.66

Pivot Points

R3$1.52

R2$1.47

R1$1.40

Pivot Point$1.34

S1$1.27

S2$1.22

S3$1.15

Advanced Oscillators

TSI-31.94

Ultimate Osc23.3

KST-137.40

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$82,242	$0	$0	$0	$64,800	$0
Cost of Revenue	$0	$0	$-4,874,167	$0	$0	$0	$21,307	$0	$0	$0	$23,589	$0
Gross Profit	$0	$0	$4.87M	$0	$0	$0	$-21,307	$0	$0	$0	$-23,589	$0

Operating Expenses	$4.68M	$5.35M	$4.47M	$4.79M	$5.09M	$4.37M	$3.33M	$4.46M	$8.18M	$4.38M	$4.41M	$4.89M
R&D	$2.14M	$2.76M	$2.35M	$2.85M	$2.76M	$2.26M	$1.22M	$2.62M	$4.44M	$2.51M	$2.37M	$2.37M
SG&A	$2.54M	$2.59M	$2.12M	$1.94M	$2.33M	$2.11M	$2.11M	$1.84M	$3.75M	$1.87M	$2.03M	$2.52M
Operating Income	$-4,681,652	$-5,353,545	$-4,466,023	$-4,785,777	$-5,089,526	$-4,369,376	$-3,331,104	$-4,458,964	$-8,182,824	$-4,377,700	$-4,407,230	$-4,885,005

Interest Income	$61,062	$93,052	$83,339	$78,074	$42,568	$40,413	$51,857	$105,405	$84,531	$115,303	$0	$0
Interest Expense	$0	$72,121	$1,442	$0	$578,356	$60,173	$0	$15,734	$0	$0	$302,237	$-106,000
Income Before Tax	$-4,571,501	$-5,425,666	$-4,467,465	$-4,735,085	$-5,667,882	$-4,429,549	$-3,263,489	$-4,474,698	$-8,141,869	$-3,994,320	$-4,709,467	$-4,696,807
Income Tax Expense	$104,070	$183,066	$70,116	$549,288	$141,205	$100,509	$504,738	$10,994	$1,209	$19,874	$14,502	$21,456

Net Income	$-4,675,571	$-5,608,732	$-4,537,581	$-5,284,373	$-5,809,087	$-4,530,058	$-3,768,227	$-4,485,692	$-8,143,078	$-4,014,194	$-4,723,969	$-4,718,263

EBITDA	$-4,605,393	$-5,497,415	$-4,522,563	$-4,790,342	$-5,688,122	$-4,449,302	$-3,294,039	$-4,558,460	$-8,205,807	$-4,089,095	$-4,792,148	$-4,782,298
EBIT	$-4,632,563	$-5,518,718	$-4,550,804	$-4,813,159	$-5,710,450	$-4,469,962	$-3,315,346	$-4,580,103	$-8,226,400	$-4,109,623	$-4,815,737	$-4,802,807

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about GANX

News

Is Gain Therapeutics (NASDAQ:GANX) In A Good Position To Invest In Growth?

Gain Therapeutics (NASDAQ:GANX) is an unprofitable biotechnology company with a cash burn rate of US$19 million last year...

Simply Wall Street•Oct 14, 2026 8:10 AM ET10/14/26•Bearish

Gain Therapeutics to Attend the 2026 Maxim Growth Summit

Gain Therapeutics, Inc. announced its participation in the 2026 Maxim Growth Summit, scheduled from October 12th to 14th at The Hard Rock Hotel New York. The clinical-stage biotechnology company will engage in one-on-one...

www.marketscreener.com•Oct 8, 2026 6:57 AM ET10/8/26•Somewhat-Bullish

HC Wainwright & Co. reiterates Buy rating on Gain Therapeutics, $8 price target

HC Wainwright & Co. has reiterated its Buy rating on Gain Therapeutics (GANX) with an $8 price target, representing a significant upside from its recent closing price. The positive outlook is supported by strong...

TradingView•Oct 6, 2026 3:28 AM ET10/6/26•Bullish

BTIG reiterates Buy on Gain Therapeutics stock on trial data By Investing.com

BTIG has reiterated a Buy rating and a $5.00 price target for Gain Therapeutics (NASDAQ: GANX) after reviewing long-term data from the company's Phase 1b study of rexaceract for Parkinson’s disease. The data indicated...

Investing.com South Africa•Oct 5, 2026 5:33 PM ET10/5/26•Neutral

BTIG reiterates Buy on Gain Therapeutics stock on trial data

BTIG has reiterated a Buy rating and a $5.00 price target for Gain Therapeutics (NASDAQ:GANX) after the company presented promising long-term data from its Phase 1b study of rexaceract for Parkinson’s disease. The data...

Investing.com•Oct 5, 2026 1:33 PM ET10/5/26•Bullish

GANX Valuation and Fair Value

P/E: -2.7x
P/B: 5.1x

See GNG's fair value

GANX Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROIC: -167.7%
ROE: -268.3%

GANX Competitors

Company	Ticker
Daxor Corporation	DXR
Connect Biopharma Holdings Ltd	CNTB
Tenax Therapeutics Inc	TENX
Pheton Holdings Ltd Class A Ordinary Shares	PTHL
ZEN Graphene Solutions Ltd	ZTEK
RenovoRx Inc	RNXT
MDxHealth SA	MDXH
Talphera Inc.	TLPH

Sector: Healthcare

GANX Analyst Ratings

Consensus: Buy
Analysts: 5
Strong Buy: 1
Buy: 4
Hold: 0
Sell: 0
Strong Sell: 0

GANX Bull Case vs Bear Case

Bull case

GANX beat EPS estimates in 75.0% of its last 8 reported quarters.
100.0% of GANX's analyst ratings are Buy or Strong Buy.

Bear case

GANX's quarterly revenue changed -100.0% year over year.

GANX Earnings: Beat Rate and Next Report

Beat rate: 6 of 8 quarters (75.0%)
Average surprise: 15.4%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.13
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 1 up, 0 down

Frequently Asked Questions About GANX

Does GANX pay dividends?

Gain Therapeutics Inc (GANX) does not currently pay a regular dividend.

What is GANX's market cap?

Gain Therapeutics Inc (GANX) has a market capitalization of $57.61M with a current stock price of $1.33.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In